“Bipolar Trans Carotenoids Salts and Their Uses”“These new patents are important additions to our intellectual property portfolio, providing strong protection through at least 2027,” said David G. Kalergis, Diffusion’s CEO.
Currently the Company has 7 issued U.S. patents, 10 issued foreign patents and more than 70 pending patent applications filed in all major international markets.
About TSC
Trans sodium crocetinate (TSC) is a proprietary, first-in-class oxygen diffusion enhancing compound formulated for IV delivery. Based on a novel mechanism of action, TSC safely re-oxygenates hypoxic tissue without causing hyper-oxygenation of normal tissue. Published studies demonstrate a tripling of survival and superior tumor control when TSC is combined with radiation and chemotherapy in animal models of primary brain cancer.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals is a clinical-stage company developing first-in-class drugs which target the numerous unmet medical needs characterized by oxygen deprivation (hypoxia) at the cellular level. These proprietary small molecules work by a novel mechanism of action that enhances the diffusion of oxygen selectively to hypoxic tissue. Potential breakthrough clinical applications include oncology, cardiovascular diseases, stroke and respiratory disorders. Diffusion’s lead program is the use of TSC in the treatment of solid cancerous tumors. A phase I/II clinical study of TSC dosed concomitantly with radiation and chemotherapy in newly diagnosed GBM patients is currently enrolling patients. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia.
No comments:
Post a Comment